Nanomaterials for Fighting Multidrug-Resistant Biofilm Infections

Employing Copper-Based Nanomaterials to Combat Multi-Drug-Resistant Bacteria

The rise of multi-drug-resistant (MDR) bacteria poses a severe global threat to public health, necessitating the development of innovative therapeutic strategies to overcome these challenges. Copper-based nanomaterials have emerged as promising agents due to their intrinsic antibacterial properties, cost-effectiveness, and adaptability for multifunctional therapeutic approaches. These materials exhibit exceptional potential in advanced antibacterial therapies, including chemodynamic therapy (CDT), photothermal therapy (PTT), and photodynamic therapy (PDT). Their unique physicochemical properties, such as controlled ion release, reactive oxygen species (ROS) generation, and tunable catalytic activity, enable them to target MDR bacteria effectively while minimizing off-target effects. This paper systematically reviews the mechanisms through which Cu-based nanomaterials enhance antibacterial efficiency and emphasizes their specific performance in the antibacterial field. Key factors influencing their antibacterial properties-such as electronic interactions, photothermal characteristics, size effects, ligand effects, single-atom doping, and geometric configurations-are analyzed in depth. By uncovering the potential of copper-based nanomaterials, this work aims to inspire innovative approaches that improve patient outcomes, reduce the burden of bacterial infections, and enhance global public health initiatives.

Effective killing of Mycobacterium abscessus biofilm by nanoemulsion delivery of plant phytochemicals

Mycobacterium is an acid-fast, aerobic, non-motile, and biofilm-forming bacterium. The increasing prevalence of mycobacterial infections makes it necessary to find new methods to combat the resistance of bacteria to conventional antibiotics. Mycobacterium abscessus is an emerging pathogen that is intrinsically drug resistant due to several factors, including an impermeable cell envelope, drug efflux pumps, target-modifying enzymes, and the ability to form thick, robust biofilms. Phytochemicals are promising antimicrobials; however, their poor solubility in water and their inability to penetrate biofilms render them inefficient in killing bacterial biofilms. In this study, we demonstrate the efficacy of polymer-stabilized phytochemical nanoemulsions in killing M. abscessus biofilms. These nanoemulsions improve the solubility and stability of the phytochemicals and enable biofilm penetration and eradication. We show that the phytochemical emulsions effectively eliminated M. abscessus in an in vitro biofilm model and killed non-replicating persister cells in the Wayne hypoxia model. These nanoemulsions were also effective in vivo in a wound infection model. These findings demonstrate the potential of polymer-stabilized phytochemical nanoemulsions as a promising alternative to conventional antibiotics for the treatment of mycobacterial infections.

IMPORTANCE

Mycobacterium abscessus is among the opportunistic bacterial pathogens that cause nontuberculous mycobacterial diseases. The infection caused by M. abscessus is difficult to treat because the bacterium is resistant to many of the currently available antibiotics, limiting chemotherapeutic strategies. Furthermore, it forms biofilms in clinically relevant settings, making the infection difficult to treat. Many phytochemicals have potent antimicrobial activities, but their hydrophobicity limits clinical applications. In this study, we tested a new drug delivery strategy where hydrophobic plant phytochemicals were emulsified with a biodegradable nanosponge. We show that the emulsification makes phytochemicals such as carvacrol and eugenol more effective against M. abscessus biofilms. We further demonstrate that nanoemulsified phytochemicals can kill hypoxia-induced dormant M. abscessus and effectively improve skin wound infection in mice. Our data pave the way to use phytochemical nanosponge as a platform to create synergy by combining other antimycobacterial drugs.

Challenges and considerations in liposomal hydrogels for the treatment of infection

INTRODUCTION

Liposomal hydrogels are novel drug delivery systems that comprise preformed liposomes incorporated in hydrogels destined for mostly localized drug therapy, herewith antimicrobial therapy. The formulation benefits from versatility of liposomes as lipid-based nanocarriers that enable delivery of various antimicrobials of different lipophilicities, and secondary vehicle, hydrogel, that assures better retention time of formulation at the infection site. Especially in an era of alarming antimicrobial resistance, efficient localized antimicrobial therapy that avoids systemic exposure of antimicrobial and related side effects is crucial.

AREAS COVERED

We provide an overview of liposomal hydrogels that were developed for superior delivery of antimicrobials at different infections sites, with focus on skin and vaginal infections. The review summarizes the challenges of infection site and most common infection-causing pathogens and offers commentary on most relevant features the formulation needs to optimize to increase the therapy outcome. We discuss the impact of liposomal composition, size, and choice of polymer-forming hydrogel on antimicrobial outcome based on the literature overview and own experience in the field.

EXPERT OPINION

Liposomal hydrogels offer improved therapy outcome in localized antimicrobial therapy. By fine-tuning of liposomal as well as hydrogel properties, formulations with superior performance can be optimized targeting specific infection site.

Design of Ultrasound-Driven Charge Interference Therapy for Wound Infection

Wound infections, especially those caused by pathogenic bacteria, present a considerable public health concern due to associated complications and poor therapeutic outcomes. Herein, we developed antibacterial nanoparticles, namely, PGTP, by coordinating guanidine derivatives with a porphyrin-based sonosensitizer. The synthesized PGTP nanoparticles, characterized by their strong positive charge, effectively disrupted the bacterial biosynthesis process through charge interference, demonstrating efficacy against both Gram-negative and Gram-positive bacteria. Additionally, PGTP nanoparticles generated reactive oxygen species under ultrasound stimulation, resulting in the disruption of biofilm integrity and efficient elimination of pathogens. RNA-seq analysis unveiled the detailed mechanism of wound healing, revealing that PGTP nanoparticles, when coupled with ultrasound, impair bacterial metabolism by interfering with the synthesis and transcription of amino acids. This study presents a novel approach to combatting wound infections through ultrasound-driven charge-interfering therapy, facilitated by advanced antibacterial nanomaterials.

Polymeric Nanoparticles for Drug Delivery

The recent emergence of nanomedicine has revolutionized the therapeutic landscape and necessitated the creation of more sophisticated drug delivery systems. Polymeric nanoparticles sit at the forefront of numerous promising drug delivery designs, due to their unmatched control over physiochemical properties such as size, shape, architecture, charge, and surface functionality. Furthermore, polymeric nanoparticles have the ability to navigate various biological barriers to precisely target specific sites within the body, encapsulate a diverse range of therapeutic cargo and efficiently release this cargo in response to internal and external stimuli. However, despite these remarkable advantages, the presence of polymeric nanoparticles in wider clinical application is minimal. This review will provide a comprehensive understanding of polymeric nanoparticles as drug delivery vehicles. The biological barriers affecting drug delivery will be outlined first, followed by a comprehensive description of the various nanoparticle designs and preparation methods, beginning with the polymers on which they are based. The review will meticulously explore the current performance of polymeric nanoparticles against a myriad of diseases including cancer, viral and bacterial infections, before finally evaluating the advantages and crucial challenges that will determine their wider clinical potential in the decades to come.